MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Ocular Therapeutix Inc

Fermé

SecteurSoins de santé

10.78 8.56

Résumé

Variation du prix de l'action

24h

Actuel

Min

9.85

Max

10.79

Chiffres clés

By Trading Economics

Revenu

-16M

-64M

Ventes

-6.4M

11M

Marge bénéficiaire

-602.342

Employés

274

EBITDA

-20M

-64M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+77.42% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

206M

1.5B

Ouverture précédente

2.22

Clôture précédente

10.78

Sentiment de l'Actualité

By Acuity

61%

39%

162 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Ocular Therapeutix Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juil. 2025, 15:46 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250 Million Private Placement

9 juil. 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 20:26 UTC

Résultats

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 juil. 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 juil. 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 juil. 2025, 17:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 juil. 2025, 16:14 UTC

Acquisitions, Fusions, Rachats

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 juil. 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 juil. 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 juil. 2025, 15:31 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250M Private Placement

9 juil. 2025, 15:31 UTC

Market Talk
Acquisitions, Fusions, Rachats

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 juil. 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 juil. 2025, 14:36 UTC

Acquisitions, Fusions, Rachats

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 juil. 2025, 14:31 UTC

Acquisitions, Fusions, Rachats

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 juil. 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 juil. 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparaison

Variation de prix

Ocular Therapeutix Inc prévision

Objectif de Prix

By TipRanks

77.42% hausse

Prévisions sur 12 Mois

Moyen 17.6 USD  77.42%

Haut 22 USD

Bas 14 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

11

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

6.97 / 7.62Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

162 / 376Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.